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Chronic myeloid leukemia (CML) is a chronic 
myeloproliferative neoplasm, resulting from a 
reciprocal translocation between chromosomes 
9 and 22, t(9;22)(q34;q11). This lesion was the 
first recurrent chromosomal abnormality de-
scribed in cancer (Nowell and Hungerford, 1960; 
Rowley, 1973) and generates the BCR-ABL 
oncoprotein, a constitutively activated protein 
tyrosine kinase (TK; Deininger et al., 2000). 
Mouse models and human data have demon-
strated BCR-ABL expression to be causative 
in CML (Daley et al., 1990; Heisterkamp et al., 
1990; Zhao et al., 2001; Ramaraj et al., 2004; 
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The introduction of highly selective ABL-tyrosine kinase inhibitors (TKIs) has revolutionized 
therapy for chronic myeloid leukemia (CML). However, TKIs are only efficacious in the 
chronic phase of the disease and effective therapies for TKI-refractory CML, or after pro-
gression to blast crisis (BC), are lacking. Whereas the chronic phase of CML is dependent 
on BCR-ABL, additional mutations are required for progression to BC. However, the identity 
of these mutations and the pathways they affect are poorly understood, hampering our 
ability to identify therapeutic targets and improve outcomes. Here, we describe a novel 
mouse model that allows identification of mechanisms of BC progression in an unbiased 
and tractable manner, using transposon-based insertional mutagenesis on the background 
of chronic phase CML. Our BC model is the first to faithfully recapitulate the phenotype, 
cellular and molecular biology of human CML progression. We report a heterogeneous and 
unique pattern of insertions identifying known and novel candidate genes and demonstrate 
that these pathways drive disease progression and provide potential targets for novel 
therapeutic strategies. Our model greatly informs the biology of CML progression and 
provides a potent resource for the development of candidate therapies to improve the 
dismal outcomes in this highly aggressive disease.
© 2015 Giotopoulos et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/ 
by-nc-sa/3.0/).
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levels of BCR-ABL protein can indeed increase in the transi-
tion from CP to BC (Gaiger et al., 1995). However, to date, 
only a small number of mutations in specific pathways have 
been associated with disease progression in CML. For exam-
ple, mutations or deletions in TP53, ASXL1, and RUNX1 
are commonly described in myeloid BC at frequencies rang-
ing between 3 and 25% (Ahuja et al., 1989; Grossmann et al., 
2011), 15 and 20% (Boultwood et al., 2010; Grossmann et al., 
2011), and 13 and 33% (Grossmann et al., 2011; Zhao et al., 2012) 
of cases, respectively. Similarly, mutations or deletions in the 
CDKN2A/B and IKAROS genes have been reported in up 
to 50 and 80% of patients in lymphoid BCs, respectively (Sill 
et al., 1995; Mullighan et al., 2008). Modern sequencing tech-
nologies and lowered costs have refined the mutational land-
scape for many tumors (Pleasance et al., 2010a,b; Curtis et al., 
2012; Cancer Genome Atlas Research Network, 2013), but as 
yet have only been used in a directed fashion in CML (Piccaluga 
et al., 2009; Boultwood et al., 2010; Grossmann et al., 2011). 
Therefore, the spectrum of mutations that cooperate with 
BCR-ABL and the majority of pathways and processes that 
are corrupted by these mutations during the progression of 
CML to advanced phases, particularly for myeloid transfor-
mation, have yet to be fully described.
Mouse models have greatly informed cancer biology in gen-
eral and CML in particular. Several models have been previously 
generated, in which transgenic BCR-ABL expression is driven 
by several different promoters after either germline or retroviral 
integration (Hariharan et al., 1989; Castellanos et al., 1997; 
Honda et al., 1998; Huettner et al., 2000, 2003; Koschmieder 
et al., 2005). However, many of these models have failed to re-
capitulate the human disease by either generating predominantly 
acute lymphoid leukemias that lacked a preceding chronic phase, 
or a very rapidly fatal myeloproliferative neoplasm (MPN)–like 
disease not resembling the human counterpart (Daley et al., 
1990; Honda et al., 1998; Huettner et al., 2000; Huettner et al., 
2003). Models of BC have also been reported, where BCR-
ABL expression has been combined with a known second hit, 
such as p53 or Dok1/Dok2 loss, or NUP98-HOXA9 or Hes1 
overexpression (Skorski et al., 1996; Honda et al., 2000; Dash 
et al., 2002; Yasuda et al., 2004; Neering et al., 2007). Although 
confirmatory of the cooperation of specific mutations with 
BCR-ABL, these models have not informed the broader biol-
ogy of BC due to their directed nature. Previous attempts to 
model random secondary mutations using retroviral inser-
tional mutagenesis have also proven of limited value, with two 
reported studies only documenting three common inser-
tions (Notch 1, Zfp423, and BCR-ABL; Mizuno et al., 2008; 
Miyazaki et al., 2009). Furthermore, the majority of these mod-
els have generated lymphoid leukemias, mainly T-ALL, thereby 
reducing their relevance for human disease.
We therefore set out to generate a novel mouse model of 
CML progression that would allow us to identify mechanisms 
of BC progression in an unbiased and tractable manner. Here, 
we have combined a mouse transposon-based insertional muta-
genesis system with a published transgenic mouse model of 
chronic phase CML (Koschmieder et al., 2005). For the first 
Koschmieder et al., 2005), and this observation has led to the 
paradigmic development of potent small molecule inhibitors 
that selectively target ABL enzymatic function and interrupt 
its oncogenic TK activity. Imatinib mesylate, the prototypic 
ABL tyrosine kinase inhibitor (TKI), and subsequent second 
and third generation TKIs, have revolutionized CML treat-
ment (Druker et al., 1996; 2006; Carroll et al., 1997; Heinrich 
et al., 2000; O’Brien et al., 2003), significantly improving cy-
togenetic and molecular response rates, keeping the majority 
of patients in chronic phase, and prolonging overall survival 
(Druker et al., 2001, 2006; Sawyers et al., 2002; Hughes et al., 
2003). However, despite this vast improvement, significant clin-
ical challenges still remain in CML therapy. CML stem cells 
appear relatively resistant to the effects of TKIs (Copland et al., 
2006; Jørgensen et al., 2007; Konig et al., 2008) such that, in 
the majority of patients, CML is controlled rather than cured. 
In addition, resistance occurs and this, together with stem cell 
persistence, facilitates disease transformation. Three distinct phases 
of the disease have been described. The initial phase, in which 
85–90% of patients are diagnosed, is the indolent chronic 
phase (CP), which is readily amenable to treatment. However, 
without adequate therapy, this almost inevitably progresses to 
an aggressive acute leukemia of myeloid or lymphoid phe-
notype (70 and 30%, respectively), termed blast crisis (BC), 
which may be preceded by an ill-defined intermediate or ac-
celerated phase (AP; during which the levels of myeloblasts in 
the BM or peripheral blood (PB) are increased but remain 
<20%). 10–15% of patients present beyond CP and a small 
percentage of CP cases continue to transform even on TKI 
therapy. The frequency of transformation is recorded at 3–5% 
within the first few years of TKI therapy but drops to 1% per 
year thereafter in randomized trials (Druker et al., 2006), al-
though these values have been found to be higher in population-
based studies (de Lavallade et al., 2008; Gallipoli et al., 2011). 
Treatment options for AP and BC are very limited, with re-
sponse rates to TKIs lower and much less durable. Other options 
involve highly toxic therapies, such as combination chemo-
therapy and BM transplantation, and are not available or ap-
propriate for many patients with progression. Therefore, even 
in the TKI era, the median survival of patients with BC is still 
dismal at around 6 mo (Hehlmann and Saussele, 2008; Silver 
et al., 2009), defining it as an unmet clinical need.
Although the chronic phase of CML appears almost entirely 
dependent on BCR-ABL and CML is regarded as an invalu-
able model of leukemic evolution, the molecular mechanisms 
underlying disease progression are still poorly annotated. It is 
generally accepted that additional mutations cooperate with 
BCR-ABL during progression to BC (Calabretta and Perrotti, 
2004), as is demonstrated by the observation that >75% 
of BC patients harbor additional cytogenetic abnormalities 
(Mitelman and Levan, 1978; Radich, 2007). There is also good 
evidence that the BCR-ABL protein itself contributes to the 
acquisition of further mutations, through its effects on reactive 
oxygen species induction, DNA damage, DNA repair, apop-
tosis, and cellular growth (Perrotti et al., 2010; Nieborowska-
Skorska et al., 2012; Bolton-Gillespie et al., 2013), and the 
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and ongoing mutagenesis. The expression levels of BCR-
ABL were similar between CML and BC animals and com-
parable to human CML samples (Fig. 2 B). Upon withdrawal 
of tetracycline, both CML and BC animals developed a mod-
erate, but persistent (2–3-fold), increase of white blood counts 
(WBCs), with a marked expansion of the granulocyte com-
partment, as has been previously reported (Koschmieder et al., 
2005). The two groups showed similar early disease kinetics, 
as assessed by serial WBC, regardless of the length of time from 
BCR-ABL expression and transposition (Fig. 2 C). However, 
BC mice demonstrated a dramatic preterminal proliferative 
change in the kinetics of their disease, with a marked increase 
in terminal WBC in comparison with CML mice (Fig. 2 D 
illustrates individual cases and Fig. 3 B averaged terminal WBC). 
These data demonstrate an explosive alteration in the clinical 
nature of the leukemia, similar to the usual clinical presenta-
tion in patients with AP/BC.
Transposition generates myeloid BC
In addition to significant differences in disease latency, the 
experimental cohorts demonstrated marked macroscopic and 
microscopic differences in leukemia phenotype. All mice un-
derwent macroscopic analysis at necropsy to determine the 
degree of splenomegaly and liver weight, as well as terminal 
WBC analysis, cytological analyses of PB smears, and BM cy-
tospins, histology sections, and immunophenotyping by FACS. 
Individual cases were classified according to the Bethesda 
criteria for mouse hematological tumors (Kogan et al., 2002; 
Morse et al., 2002). As expected, all CML animals remained 
in the chronic phase of the disease. Animals belonging to the 
SB group developed both lymphoid (26%) and myeloid 
(70%) acute leukemias. However, in marked contrast to both 
of these cohorts, an exclusively myeloid and primarily acute 
leukemia phenotype was seen in the majority of the BC 
group (85%; Fig. 3 A). A small proportion of BC animals 
(5%) remained in the chronic phase of the disease and were 
indistinguishable from CML mice, whereas 10% of BC an-
imals developed an AP-like phenotype, distinguishable from 
CML mice but with <20% blasts. These findings demon-
strate a disease continuum in the progression cohort, similar 
to human CML (Fig. 3 A). Compared with the CML cohort, 
WBC counts at the terminal endpoint were significantly ele-
vated (Fig. 3 B; P < 0.0001 vs. CML) and hemoglobin levels 
were decreased in the BC cohort (P < 0.001 vs. CML and P = 
0.03 vs. SB). Spleen and liver weight were also significantly 
increased (P < 0.001 vs. CML) in BC mice. Examination of 
histological and cytospin preparations of PB, BM, and vis-
ceral organs demonstrated increased infiltration of tissues with 
both granulocytes and immature cells in BC mice, whereas 
only immature cells were seen in SB mice (Fig. 3 C). Inter-
estingly, disease progression in the BC mice was frequently 
accompanied by a marked increase in basophils, an extremely 
rare cell type in mice, but a typical feature of disease progres-
sion in the human disease (Fig. 3 D). Assessment by flow cy-
tometry confirmed the absence of lymphoid leukemias in the 
BC, but not in the SB cohorts (0 vs. 26%; P < 0.0001; Fisher’s 
time, we report a BC model that closely mimics the natural 
progression of human CML and faithfully recapitulates the cel-
lular and molecular aspects of its biology. We have identified 
known and novel candidate genes and pathways that, in combi-
nation with BCR-ABL, drive disease progression and could act 
as potential therapeutic targets in BC. Our novel model there-
fore defines mechanisms of CML progression, identifies thera-
peutic targets and provides a translational resource to improve 
clinical outcomes in this aggressive disease.
RESULTS
Generation of a mouse model of CML progression
The CML and mutagenesis systems have been previously de-
scribed (Koschmieder et al., 2005; March et al., 2011; Vassiliou 
et al., 2011). In brief, BCR-ABL (p210) was expressed in the 
hematopoietic stem and progenitor cell (HSPC) compartment 
under the control of the mouse 3-SCL enhancer (Sánchez et al., 
1999) in a tetracycline-dependent manner (Fig. 1 A). Forward 
mutagenesis was conditionally induced after Mx1-Cre–mediated 
inversion of the Rosa26flox-SB allele, leading to transposase ex-
pression and transposition of GrOnc, a Sleeping Beauty (SB) 
transposon (Fig. 1 A). To prevent undesired BCR-ABL ex-
pression or transposition before the generation of our ex-
perimental cohort, SCLtTATg/wt mice were crossbred with 
Rosa26flox-SB/wt mice to generate SCLtTATg/wt; Rosa26flox-SB/wt 
mice and TRE-BCR-ABLTg/wt mice were crossbred with 
Mx1-CreTg/wt; GrOncTg/wt mice to ultimately generate TRE-
BCR-ABLTg/Tg; Mx1-CreTg/Tg; GrOncTg/Tg mice (Fig. S1 A). 
Fig. 1 B illustrates the final cross that generated our four ex-
perimental genotypes: TRE-BCR-ABLTg/wt; Mx1-CreTg/wt; 
GrOncTg/wt; SCLtTATg/wt; Rosa26flox-SB/wt (hereafter BC), which 
constituted the CML-mutagenesis cohort; TRE-BCR-ABLTg/wt; 
Mx1-CreTg/wt; GrOncTg/wt; SCLtTATg/wt; Rosa26wt/wt (hereafter 
CML), which constituted the CML-only cohort; TRE-BCR-
ABLTg/wt; Mx1-CreTg/wt; GrOncTg/wt; SCLtTAwt/wt; Rosa26flox-SB/wt 
(hereafter SB), which constituted the mutagenesis-only cohort; 
and TRE-BCR-ABLTg/wt; Mx1-CreTg/wt; GrOncTg/wt; SCLtTAwt/wt; 
Rosa26wt/wt (hereafter wt), which were used as WT controls. 
The TRE-BCR-ABL and SCLtTA mice were on an FVB/N 
background, whereas the remaining elements were on a 
C57BL/6 background (i.e., the experimental cohorts were on 
a mixed genetic background). To induce expression of BCR-
ABL and initiate mutagenesis, respectively, tetracycline was 
withdrawn from the drinking water and 5–8-wk-old mice 
were treated with 5 doses of polyinosine-polycyticylic acid 
(pIpC; Fig. 1 C). Successful expression of BCR-ABL and in-
version of the SB transposase and transposon mobilization 
were confirmed by PCR of PB samples (Fig. 2, B and C; and 
not depicted).
Transposition in BC mice leads to CML progression  
and decreased survival
Overall, BC mice demonstrated a decreased survival (me-
dian, 116.5 d) compared with both CML (median, 149 d; 
P < 0.0001) and SB mice (median, 125.5 d; P = 0.0054; Fig. 2 A), 
a strong indication of a cooperative effect between BCR-ABL 
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expanded in the BC mice (Fig. 4 A; P < 0.0024). This expan-
sion of myeloid progenitors, including the GMP compartment 
(Fig. 4, A and B; P = 0.0116), is in agreement with previous 
reports in human CML progression, where patients in BC or 
resistant to Imatinib demonstrated an expansion of the GMP 
pool (Jamieson et al., 2004). Whereas there was no difference 
in lymphoid compartment size between BC and CML mice, 
both demonstrated a marked decrease of lymphoid potential 
when compared with age-matched WT mice (Fig. 4 A; P < 
0.001), with this feature potentially explaining the absence of 
lymphoid BCs in our model.
To assess any alterations in HSPC function upon CML 
progression, we next performed serial replating assays to as-
sess the self-renewal potential of BC and CML progenitors 
in vitro. BC cells demonstrated an increased ability to serially 
replate by comparison with CML and age-matched WT mice 
exact test, two tailed; Fig. 3 E). These data demonstrate that 
BCR-ABL synergizes with the GrOnc transposon to promote 
myeloid but not lymphoid leukemogenesis, recapitulating 
many clinical and laboratory aspects of human myeloid BC.
Transposition alters the size and function of the  
HSPC compartment
To characterize alterations in the HSPC compartment after dis-
ease progression, we next extended our flow cytometry analyses 
to this compartment, comparing CML and BC mice. BC mice 
demonstrated a significant expansion of the lineage-negative 
(Lin) BM fraction (Fig. 4 A; P < 0.0001), but no significant 
differences in total LinSca+c-kit+ (LSK) numbers, long-term 
and short-term hematopoietic stem cell (HSC), or multipo-
tent progenitor proportions (Fig. 4 A and Fig. S1 B). In con-
trast, the myeloid progenitor compartment was significantly 
Figure 1. Generation of a mouse model 
of CML progression. (A) Expression of p210 
BCR-ABL (TRE-BCR-ABL) is driven by an SCL 
3 enhancer element (SCLtTA transactivator) 
in a tetracycline-dependent manner (adapted 
from Koschmieder et al., 2005). Upon pIpC-
induced and Mx1-Cre–mediated inversion, the 
Sleeping Beauty (SB) transposase (Rosa26flox-SB) 
is expressed and facilitates transposition of 
the GrOnc transposon. The transposon con-
struct contains a concatamer of 80 U of the 
Graffi1.4 virus long terminal repeat (Gr1.4 
LTR), splice acceptors (SA), bi-directional ad-
enovirus polyadenylation signals (pA), and a 
splice donor (SD), all flanked by SB inverted 
repeats (adapted from March et al., 2011; 
Vassiliou et al., 2011). (B) The parental lines 
were established as described in Fig. S1. The 
experimental cohorts were generated by 
crossing TRE-BCR-ABLTg/Tg, GrOncTg/Tg, Mx1-
CreTg/Tg mice with SCL-tTATg/wt, Rosa26flox-SB/wt 
mice, in the presence of tetracycline. (C) Upon 
weaning, mice were taken off tetracycline and 
treated with 5 doses of pIpC, simulating the 
temporal sequence of human BC transforma-
tion where mutagenesis occurs in the pres-
ence of BCR-ABL expression, leading to 
disease progression from a CML to BC phase. 
A CML phenotype was detected as early as  
14 d and BC from as early as 40 d after tetra-
cycline withdrawal.
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expression between the CML and BC mice (Fig. 5 A). Hierar-
chical clustering of gene expression in 5 CML and 10 BC cases 
demonstrated consistency between gene expression and gen-
otype, with CML and BC mice clustering separately. In total, 
2,252 genes were differentially expressed between the two 
groups (910 up-regulated and 1,342 down-regulated upon dis-
ease progression, twofold gene expression difference; Fig. 5 B 
and Table S1). The expression levels of several genes were vali-
dated by qRT-PCR, notably genes that have previously been 
reported as deregulated in CML progression (Fig. 5 C; Guerrasio 
et al., 1994; Shimamoto et al., 1995; Radich et al., 2006; Ricci 
et al., 2009). To test for similarities with human BCs, we then 
used Gene Set Enrichment Analysis (GSEA; Subramanian 
et al., 2005) to directly compare our dataset with a widely 
used human CML-BC dataset (Radich et al., 2006). As illus-
trated in Fig. 5 D, our expression profiles were significantly 
enriched in genes reported to be both up- and down-regulated 
during progression to BC, demonstrating distinct similarities 
at the gene expression level between our mouse model and 
the corresponding human disease. Interestingly, additional GSEA 
(Fig. 4 C). To test their self-renewal in vivo, we performed 
transplantation experiments using sublethally irradiated NOD-
SCID mice as recipients. Both CML and BC cells were able 
to propagate their respective diseases in vivo, albeit with a 
compromised efficiency. As shown in Fig. 4 D, a significant 
increase in self-renewal is demonstrated in BC cases, where 
the rates of engraftment, disease transfer, and death were twice 
that of the CML mice. The disease latency was also signifi-
cantly shorter (median survival 55.5 d for BC and >60 d for 
CML; P = 0.02). Collectively, these results confirm a dramatic 
alteration of HSPC regulation and function after transposi-
tion and CML progression, with an expansion of the myeloid 
progenitor compartments and an acquisition of enhanced self-
renewal demonstrated both in vitro and in vivo.
Disease progression induces gene expression changes  
similar to human BC
To determine molecular drivers of BC, we next examined alter-
ations in gene expression that occurred after CML progres-
sion. Microarray analysis revealed distinct differences in gene 
Figure 2. Transposition leads to de-
creased survival and CML progression.  
(A) Kaplan-Meier curves showing survival of 
BC (n = 56) mice compared with CML (n = 41; 
P < 0.0001), SB (n = 30; P < 0.0054), and WT 
(n = 10; P < 0.0001) mice. Log-rank test was 
used. (B) BCR-ABL expression levels (n = 6 
mice) were compared with human CML (n = 6 
samples; left). BC (n = 3) and CML (n = 3) 
mice demonstrated similar levels of BCR-ABL 
expression throughout the study (right). Stu-
dent’s t test was used. (C) Disease kinetics 
between CML and BC mice until the pretermi-
nal stages. Genotypic BC (dark blue) and CML 
mice (light blue) white blood counts (WBC) 
before transformation, when terminal bleeds 
for all groups of mice were excluded from the 
analysis (n = 8–26 mice at each time point). 
(D) Terminal WBC of representative BC cases 
(red) in comparison to CML mice (light blue). 
BC mice (by genotype) that remained in mor-
phological chronic phase (dark blue) before 
sacrifice are shown for comparison (n = 1–26 
mice at each time-point). Data are mean ± 
SEM. **, P < 0.01.
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using ligation-mediated PCR followed by sequencing of 
transposon insertion sites from individual leukemias (Uren 
et al., 2009; van der Weyden et al., 2011; Vassiliou et al., 2011). 
Sequencing generated 534,493 reads, subsequently aligned to 
the mouse genome with a 44.41% success. These collapsed to 
31,739 unique positions in the BC set and 18,301 unique 
positions in the SB set. 52 BC and 20 SB cases were success-
fully sequenced and statistically significant common insertion 
site (CIS) datasets were identified for each cohort. A total of 
91 CISs were identified for the BC mice and 39 for the SB, 
with an average 19.8 CISs/case for the BC mice and 22 CISs/
case for the SB mice (Fig. 6, A and B; and Tables S2 and S3). 
Insertions in chromosome 19 are listed separately to account 
for local hopping and are not represented in the circos plot, 
as chromosome 19 harbored the donor transposon concatamer. 
The number of total insertion events in the two cohorts also 
differed, with higher insertion rates in the SB (mean = 785.2 
insertions/case) compared with the BC mice (mean = 501.1 
insertions/case, P = 0.056; Fig. 6 B). These data would be in 
analysis, comparing our patterns to MSigDB-curated gene 
sets, demonstrated other germane gene signatures significantly 
enriched in the BC cases, including pathways previously re-
ported in human BCs, such as targets of NUP98-HOXA9 
(Dash et al., 2002), HIF1a (Ng et al., 2014), Rapamycin, and 
EIF4E (Lim et al., 2013; Fig. 5 E). Our gene expression pro-
files were also highly concordant with reported human BC 
cell line data. In fact, when the list of BC up-regulated genes 
was compared with up-regulated gene signatures from 947 cell 
lines in the Cancer Cell Line Encyclopedia (CCLE), using 
the EnrichR gene set analysis tool (Barretina et al., 2012; 
Chen et al., 2013a), 8/20 (40%) of the significantly similar 
human cell lines were generated from patients in BC (P = 
1.98 × 1010; hypergeometric test; Fig. 5 F).
Identification of collaborating mutations required  
for CML progression
Our model was specifically designed to identify mutations 
that collaborated with BCR-ABL during CML progression, 
Figure 3. Transposition leads to myeloid 
blast crisis. (A) Classification of all leukemias 
in each experimental cohort by the Bethesda 
criteria revealed a continuum of myeloid pro-
gression in the BC cohort with 85% demon-
strating a myeloid transformation. In the SB 
cohort, 26% of cases were of a lymphoid 
phenotype. All mice in the CML cohort re-
mained in the chronic phase of the disease. 
(B) Analysis of WBC, hemoglobin levels, and 
spleen and liver weights at the terminal end-
points between BC, CML, and SB mice (BC,  
n = 41; CML, n = 30; and SB, n = 18 for WBC 
and hemoglobin plots; BC, n = 56; CML, n = 38; 
and SB, n = 25 for liver and spleen weight 
plots). Student’s t test was used. (C) Peripheral 
blood (PB) smears, kidney, and BM histology 
sections and BM cytospins of representative 
CML, BC, and SB cases. (D) Cytospin prepara-
tions of BC BM from 4 cases showing charac-
teristic abnormal basophils (arrowed), a 
feature often seen in human BC. (E) Represen-
tative flow cytometry profiles of CML, BC, and 
SB leukemias. Data are representative of at 
least three independent experiments. Data are 
mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 
0.0001. Bar, 25 µm.
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Makishima et al., 2011; Warsch et al., 2013; Ferri et al., 2014; 
Gallipoli et al., 2014; Huang et al., 2014). In addition, several 
novel genes not known to be associated with CML progression, 
but previously implicated in hematopoiesis or leukemogenesis 
were also identified, including Jak1, Flt3, Nf1, Erg, and Mll3. At 
the level of individual cases, BC samples grouped separately from 
SB samples using unsupervised clustering (Fig. 7 A), with an in-
creased heterogeneity in the identity of their cooperating CISs 
compared with SB cases. Of interest, the number of cooperating 
CISs within an individual leukemic sample was also noted to be 
highly variable for BC cases, ranging from 1–52 insertions (me-
dian 18), with SB cases more homogeneous (insertion range 
1–29, median 16 insertions; Fig. 7 A).
Mechanisms of action of selected insertion sites and 
functional validation of cooperativity in CML progression
The GrOnc transposon can activate gene expression through 
insertion of its strong retroviral enhancer/promoter elements 
keeping with the hypothesis that fewer insertional events are 
required for leukemic transformation in the BC cohort. Of 
the 91 CISs identified in BC mice, 78 (86%) were specific to 
this cohort, whereas 26/39 (67%) CISs were unique to the 
SB cohort (Fig. 6 B), with 13 CISs shared between the two 
cohorts. Taken as a group and annotated by Gene Ontology 
(GO) terms, the BC CISs included genes involved in several 
critical cellular functions, including regulation of transcription, 
intracellular signaling, chromatin modification, and cellular 
metabolism (Fig. 6 C). These data demonstrate a high degree 
of heterogeneity in the pathways that may be affected in BC, 
very similar to the wide spectrum of dysregulation seen in other 
acute leukemias.
As shown in Fig. 6 A and Table S2, BC CISs include sev-
eral genes already suggested to be involved in the biology of 
CML and its progression, including Asxl1, Myb, Stat5b, and 
Pten (Lidonnici et al., 2008; Boultwood et al., 2010; Peng et al., 
2010; Grossmann et al., 2011; Machová Poláková et al., 2011; 
Figure 4. Progression to blast crisis is 
accompanied by changes in the frequency 
and function of hematopoietic stem and 
progenitor cells. (A) The size/composition of 
the HSC (LSK) compartment between CML and 
BC mice (n = 18 for both groups), the myeloid 
progenitor compartment, including the GMP 
fraction (n = 16 for both groups) and the 
LinIL7R+ lymphoid progenitor cell (n = 18 for 
BC and CML and n = 17 for age-matched WT 
mice) compartments were assessed by flow 
cytometry. Student’s t test was used. (B) Rep-
resentative FACS plots of the myeloid pro-
genitor and GMP compartments between BC 
and SB mice. (C) Mean colony numbers for BC 
(n = 16), CML (n = 15), and age-matched WT 
(n = 11) mice in serial replating assays. Stu-
dent’s t test was used. (D) Kaplan-Meier 
curves of secondary transplants of BC (n = 20) 
and CML (n = 25) cases into NOD-SCID recipi-
ents (P < 0.05). Log-rank test was used. Data 
are representative of at least three indepen-
dent experiments. Data are mean ± SEM.  
*, P < 0.05; **, P < 0.01; ***, P < 0.0001.
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Figure 5. Progression to BC generates gene expression profiles that are comparable to human blast crisis. (A) Unsupervised hierarchical clus-
tering of gene expression data between CML (n = 5) and BC (n = 10) cases. (B) Volcano plot for BC (n = 10) versus CML (n = 5) samples showing fold 
change (log2) and p-value significance (log10) for all genes. (C) Levels of expression for several genes previously identified to be involved in CML pro-
gression were validated by qPCR (n = 9 for BC; n = 6 for CML). Data are representative of at least three independent experiments. Student’s t test was 
used. (D) GSEA plots comparing our gene expression signature to that of a previously published human CML BC dataset. Genes down-regulated during 
human BC progression (Radich dataset down) and genes up-regulated during human BC progression (Radich dataset up). (E) GSEA plots showing enrich-
ment of previously reported genes/pathways in CML progression including targets of NUP98-HOXA9, HIF1a, and EIF4 in our dataset. (F) The EnrichR tool 
enabled comparison of our BC up-regulated genes against a gene-set library of genes highly expressed in cancer cell lines from the CCLE database.  
A significant proportion (40%) of cell lines with a significant overlap of up-regulated genes were CML BC cell lines. Data are mean ± SEM. *, P < 0.05.
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The ability of our model to faithfully recapitulate the cel-
lular and molecular phenotype of BC suggests that our co-
operating insertions are relevant for disease progression. To 
functionally test this hypothesis, we selected 4 candidate genes, 
Pten, Myb, Vegfc, and Erg for further analysis. Overexpres-
sion of PTEN in the human BC cell lines Lama-84, Meg-01, 
EM-2, and K562 led to an increased apoptotic rate by com-
parison with overexpression of an empty vector (Fig. 8 A). 
The rate of apoptosis varied between the cell lines but did 
not reflect general cellular toxicity, as expression of PTEN 
in CD34+ progenitor cells demonstrated minimal apoptosis 
(Fig. 8 A). In addition, modest knockdown of MYB and 
VEGFC (50–75% of baseline expression), using either pooled 
upstream of a gene or can alternatively result in gain or loss of 
function of genes after intragenic insertion (Ranzani et al., 
2013). We documented the insertion location for all CISs and 
predicted their effects on the function of neighboring genes, as 
is shown in Fig. 7 (B and C). These included Erg, Runx2, and 
Sox6, where insertion of the transposon occurred uniquely in 
the sense strand, either upstream of a predicted transcriptional 
start site, or in the 5 portion of the gene, leading to an up-
regulation of expression of that gene in BC in comparison to 
CML (Fig. 7, B and C; and not depicted). Conversely, for 
other genes, exemplified by the tumor suppressor gene Pten, 
intragenic insertion of the transposon on either strand led to a 
down-regulation of gene expression (Fig. 7, B and C).
Figure 6. Common insertion sites (CISs) 
in CML BC progression. (A) Circos plot of 
CISs in the BC (red) and SB (green) cohorts. 
Genes annotated in black were common to 
both cohorts. Note: chromosome 19 (the 
transposon donor) was analyzed separately 
and is not represented in this plot. (B) Pie 
chart of the CISs between the BC and SB 
groups. Bar graphs of the number of CISs per 
sample and the number of total insertion 
events between BC mice and SB mice. Stu-
dent’s t test was used. (C) Functional annota-
tion of the BC CISs according to their gene 
ontology term. BC (n = 52); SB (n = 20). Data 
are mean ± SEM. *, P < 0.05; ***, P < 0.0001.
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in the proportion of primitive cells in comparison to CML-
GFP mice and a subtle phenotypic difference, including the 
WBC, when compared with the WT-ERG cohort (Fig. 8 D). 
Collectively, these data demonstrate the relevance of our can-
didate genes to the progression of CML and show that unique 
individual CISs identified from our cohort may be sufficient, 
in cooperation with BCR-ABL, to induce myeloid BC.
Integrated analysis of insertional and transcriptional 
candidates identify potential therapeutic targets  
in CML progression
Novel therapies are urgently required for BC and the GSEA 
and transposon insertional analysis from our model identified 
several potential therapeutic targets implicated during CML 
progression. These included (targets of) MYC (Schuhmacher 
et al., 2001; Fig. 9 A), whose activation was corroborated by 
the demonstration of increased levels of MYC expression in 
CML BC samples from both our mouse model and human 
BC (unpublished data), as well as increased MYC binding at 
the promoters of known MYC targets (CDK4, TFRC, MYC, 
siRNA or shRNA, documented a significant decrement in 
colony formation, as well as increased apoptosis in the same 
BC cell lines (Fig. 8 B and not depicted). Finally, to provide a 
functional proof-of-principle for the in vivo cooperation of 
BCR-ABL with individual CISs, we retrovirally overexpressed 
ERG, our most commonly occurring CIS, or an empty vector 
in HSPC from both BCR-ABL–expressing and WT mice, 
before transplantation into congenic recipients (Fig. 8 C). Al-
though ERG overexpression alone also generated leukemia 
in recipient mice, as has been previously reported (Goldberg 
et al., 2013), overexpression of ERG on a CML background 
resulted in a marked alteration in disease phenotype. Despite 
very similar transduction efficiencies (Fig. 8 C), CML-ERG 
mice demonstrated a significantly shortened survival compared 
with WT-ERG and CML-GFP mice (Fig. 8 D; median sur-
vival 61.5 d CML-ERG vs. 115.5 d WT-ERG vs. 156 d 
CML-GFP; P = 0.0266 CML-ERG vs. wt-ERG; and P = 
0.0089 CML-ERG vs. CML-GFP, respectively). The result-
ing acute leukemias in the CML-ERG cohort phenotypically 
resembled the original BC cohort, with marked differences 
Figure 7. Transposition leads to transcriptional de-
regulation and a distinct mutational signature in the BC 
cohort. (A) Unsupervised analysis of BC (n = 52) and SB (n = 
20) insertion profiles by Euclidean distance, based on insertion 
number and identity. Each column represents an individual 
case with BC insertions in red and SB in green. (B) Insertions 
in the Erg gene were all found in the sense strand (blue ar-
rows), strong indication of activating events. Conversely, 
insertions on the Pten gene were found in both strands 
(anti-sense strand in red arrows), suggesting inactivation of 
this gene. (C) Gene expression levels of selected CIS genes 
were investigated by qRT-PCR (BC, n = 5; CML, n = 6). Data 
are representative of at least three independent experiments. 
Student’s t test was used. Data are mean ± SEM. *, P < 0.05; 
***, P < 0.0001.
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Figure 8. Functional validation of CISs candidates. (A) Representative FACS plots and bar charts showing apoptosis induction levels in BC cell lines 
and normal CD34+ cells, 72 h after retroviral overexpression of PTEN. (B) siRNA-mediated knockdown of MYB or VEGFC effects on colony formation in BC 
cell lines. (C) Schema of experimental plan. WT or BCR-ABL+ c-kit+ HSPC cells were retrovirally transduced with ERG (or empty vector control) and trans-
planted into sublethally irradiated congenic recipients. The recipient mice were placed on tumor watch. ERG mRNA levels of CML-ERG and WT-ERG trans-
duced cells (left). Engraftment levels across the four experimental cohorts in the early points after transplantation, as indicated by percentage of GFP+ cells 
(right). (D) Kaplan-Meier survival curves of CML-ERG (n = 4), CML-GFP (n = 4; P < 0.01) and WT-ERG (n = 4; P < 0.05) mice. Log-rank test was used. Bar 
charts of terminal white blood counts (Student’s t test was used) and representative photomicrographs of spleen, liver, and BM. Bar, 25 µM. Graphs in A 
and B represent three independent experiments. Student’s t test was used. Data are mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.0001.
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Figure 9. Identification and in vitro validation of potential therapeutic targets in CML progression. (A) GSEA analysis identified Myc as a po-
tential therapeutic target in BC. Representative ChIP results showing MYC binding at the promoters of known MYC targets (top). Effects of treatment 
with I-BET (24–48 h) on MYC expression (in Lama-84 and EM-2 cell lines) and mRNA levels of MYC target genes (bottom; in Lama-84, EM-2 cell lines and 
BC primary samples; n = 2). Data are representative of three independent experiments. (B) Mean colony numbers for control mouse BM (n = 3), BC mice 
(n = 3), human BC cell lines (n = 4; data represent three independent experiments; Student’s t test) and primary BC samples (n = 4; data represent two 
independent experiments) in serial replating assays using I-BET. (C) GSEA plot suggesting that the Ras–Raf–Mek–Erk pathway (inhibited by Salirasib) 
 o
n
 N
ovem
ber 2, 2015
jem.rupress.org
D
ow
nloaded from
 
Published August 24, 2015
JEM Vol. 212, No. 10
Article
1563
where both BCR-ABL expression and transposition could be 
conditionally and independently controlled, allowed us to in-
duce mutagenesis in HSPCs that already express BCR-ABL. 
This control resulted in a model that recapitulated BC at the 
clinical and histological level, also modeling alterations in the 
cellular biology of the HSPC compartment. These alterations 
included an increase in myeloid progenitor numbers, serial 
replating in methylcellulose, and an increase in in vivo disease 
transfer in transplantation experiments for BC mice and 
mirrored similar studies suggesting an increased self-renewal 
in human progression (Sirard et al., 1996; Wang et al., 1998; 
Jamieson et al., 2004). Molecularly, gene expression changes were 
identified between CML and BC mice that also mirrored al-
terations seen in patients after progression (Radich et al., 2006). 
These data demonstrate our model to very closely resemble 
human myeloid transformation and highlight blocked differ-
entiation, increased self-renewal and proliferation at the cel-
lular and molecular levels as processes required for progression.
Importantly, our BC mice also significantly differed in 
their disease phenotype from SB mice that also develop acute 
leukemia but lack BCR-ABL expression. Molecularly, BC 
and SB mice shared less than a third of their insertion sites. 
Interestingly, although there was no significant difference in 
the number of insertions between individual SB and BC leu-
kemias, the insertional spectrum was wider for BC mice with a 
more heterogeneous pattern of insertions identified (Fig. 7 A). 
This provides strong functional evidence that BCR-ABL ex-
pression provides a selective pressure for specific mutational 
partners and is more promiscuous in its partner selection. These 
data also demonstrate that BCR-ABL specifically cooperates 
with these partners to generate a unique leukemia phenotype. 
Of note, genes known to be mutated in CML (or previously 
implicated in CML biology/progression), as well as entirely 
novel genes, were identified as CISs. Collectively, these CISs 
formed complementation groups when annotated by GO term. 
These complementation groups mediated critical cellular func-
tions, including chromatin modification, transcriptional regu-
lation, and intracellular signaling, and the major groupings 
were highly reminiscent of similar subsets of mutations recently 
described from a large next generation sequencing (NGS) study 
in de novo human AML (Cancer Genome Atlas Research 
Network, 2013).
Several of our identified CISs have previously been im-
plicated in CML biology and progression, particularly those 
involved in transcriptional regulation of the HSPC compart-
ment. The most commonly identified CIS in our series was 
located in the Erg locus, with 33/52 (64%) of our BC leuke-
mias demonstrating a 5 insertion in the forward strand that 
and APEX-1; Fig. 9 A). Using an available small molecule in-
hibitor to the Bromodomain and extra-terminal (BET) pro-
teins, which regulate MYC levels and the MYC transcriptional 
program (Dawson et al., 2011), and is currently in Phase I tri-
als we were further able to demonstrate that both MYC bind-
ing, as well as transcription decreased at these MYC targets in 
human BC cells upon treatment with I-BET (Fig. 9 A). This 
correlated with a marked decrement in colony formation for 
mouse BC cells, BC cell lines (Meg-01, Lama-84, EM-2, and 
RPMI8866), and samples from BC patients after I-BET treat-
ment (Fig. 9 B and Table S4).
Insertional and GSEA analysis also identified several other 
candidates/pathways suggested to be critical mediators of CML 
progression, including Ras intermediates and the JAK/STAT 
pathway (Fig. 6 A). We therefore also tested the effects of 
inhibition of these selected targets on blast-transformed 
samples, using available small molecule inhibitors. Specifically, 
Ruxolitinib (targeting the JAK/STAT pathway; Zhou et al., 
2014), and PD0325901 and Sorafenib (targeting the MEK 
and RAF downstream mediators of Ras signaling, respectively; 
Adnane et al., 2006) were tested against mouse (Fig. 9 C) and 
human BC (Fig. 9, D and E) samples in similar methylcellu-
lose plating assays. These inhibitors were chosen for their cur-
rent usage in early phase trials or as established therapies for 
hematological and other malignancies, to allow rapid repur-
posing for formal testing in BC. No significant toxicity was 
demonstrated against normal hematopoietic cells. However, in 
marked contrast, when the same inhibitors were tested against 
representative mouse CML BC samples and human CML 
BC cell lines in similar methylcellulose colony forming as-
says, all of the inhibitors demonstrated a significant, although 
somewhat variable, decrement in colony formation, presum-
ably reflecting the molecularly heterogeneous nature of CML 
BC. Finally, similar sensitivity assays for the inhibitors were per-
formed in available samples from 4 CML BC patients (Fig. 9 E 
and Table S4). Although the degree of response again varied 
between patients, a decrease in colony formation was confirmed 
for all inhibitors. Collectively, these preliminary preclinical 
data confirm the MYC, JAK/STAT and RAS pathways as 
potential targets in BC and suggest that other novel insertion 
sites and expression patterns identified by our model may be 
important for disease progression and could therefore also be 
promising targets for treatment.
DISCUSSION
Mouse models have greatly facilitated our understanding of 
cancer biology, but have been most informative where they 
faithfully mimic aspects of the human disease. Our model, 
could be a therapeutic target in BC. Mean colony numbers for control mouse BM (n = 3), BC mice (n = 3) and human BC cell lines (n = 4) in serial replat-
ing assays using MEK (PD0325901), RAF (Sorafenib) or Jak1/2 (Ruxolitinib) inhibitors. Data represent three independent experiments. Student’s t test was 
used. (D) Mean colony numbers for four BC cell lines in serial replating assays using MEK (PD0325901), RAF (Sorafenib), or Jak1/2 (Ruxolitinib) inhibitors. 
Data represent three independent experiments. Student’s t test was used. (E) Mean colony numbers for primary BC patient samples (n = 4) in serial replat-
ing assays using MEK (PD0325901), RAF (Sorafenib), or Jak1/2 (Ruxolitinib) inhibitors. Data represent two independent experiments. Data are means ± 
SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.0001.
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Integrated analysis of insertion sites and gene expression 
data from our model identified several specific candidate targets 
and pathways amenable to therapeutic intervention, particu-
larly those related to chromatin modification and intracellular 
signaling. Chromatin and epigenetic regulators are recurrently 
mutated in myeloid malignancies (Shih et al., 2012), and the 
recent availability of potent, specific small molecule inhibitors 
of these regulators holds great therapeutic promise (Dawson 
et al., 2012). GSEA analysis of our BC-associated signature 
suggested an up-regulation of c-MYC and its targets (Fig. 9 A), 
which was confirmed by MYC binding and transcriptional 
activity, demonstrating activation of this pathways during 
BC progression. This activity was further functionally cor-
roborated, as inhibition of bromodomain and extraterminal 
(BET) proteins, critical mediators of MYC transcription, with 
I-BET demonstrated an obvious decrement in MYC binding 
and transcriptional output, as well as a decrease in clonogenic 
growth across BC samples from our mouse model, human 
BC cell lines, and patient samples. In addition, aberrant intra-
cellular signaling is well described as a hallmark of cancer 
(Hanahan and Weinberg, 2011), and evidence from integra-
tion patterns and GSEA also suggested activation of multiple 
RAS pathway members (Rabgap1l, Rasgrp1, Rapgef2, Rras2, 
Nf1, Rhot1, and Rreb1; Fig. 9 C) in BC. This prediction proved 
entirely accurate, with BC samples sensitive to inhibition of 
downstream MEK (PD0325901) and RAF (Sorafenib) path-
ways. Another major canonical signaling pathway, the JAK/
STAT pathway has recently been implicated in CML LSC 
maintenance and advocated as a clinical target in CP CML 
(Chen et al., 2013b; Neviani et al., 2013; Warsch et al., 2013; 
Gallipoli et al., 2014). Integrations in Jak1 and Stat5b in our 
model also supported evidence for its up-regulation during 
CML progression. This association further highlights the 
important link between mediators of LSC maintenance in 
CML and pathways up-regulated during progression, with the 
JAK-STAT pathway, Pten and Myb, all identified from our 
model, fulfilling this association (Lidonnici et al., 2008; Peng 
et al., 2010; Gallipoli et al., 2014). The importance of the JAK/
STAT pathway to CML progression was demonstrated by 
the significant growth retardation in BC samples after inhi-
bition with the dual JAK1/JAK2 inhibitor Ruxolitinib. 
Although the degree of inhibition varied, dependent on the 
inhibitor and sample tested, all were significant by compari-
son with control, suggesting the MYC, RAS, and JAK/STAT 
pathways to be generically activated to a greater or lesser 
degree in the majority of individual BC cases. Collectively, 
these data validate the utility of our model to identify targets 
and pathways critical for progression, to corroborate their 
role in BC maintenance, and to identify them as potential 
therapeutic targets. As our choice of inhibitors prioritized 
agents already in or close to clinical usage, these should be 
rapidly repurposed to test their efficacy in early phase trials 
of BC.
In summary, our mouse model carefully recapitulates the 
process of CML disease progression at the cellular and mo-
lecular levels, provides mechanistic detail of pathways and 
up-regulated Erg expression (Fig. 7, B and C). ERG has been 
implicated in normal and leukemia stem cell function (Diffner 
et al., 2013), is an independent predictor of poor prognosis in 
normal karypotype AML (Marcucci et al., 2005), amplified 
in up to 10% of blast-phase transformations of other MPN 
(Thoennissen et al., 2010), and has been demonstrated to be 
overexpressed during CML evolution (Kim et al., 2010). Im-
portantly, overexpression of Erg provided functional proof-
of-principle that individual CISs identified from the model 
can cooperate with BCR-ABL to generate an independent 
BC in retroviral transduction-transplantation experiments (Fig. 8 
C and D). The runt-related transcription factor Runx2 was 
our second most frequent CIS, occurring in half of the BC 
samples (26/52 cases). Of note, up to one-third of cases of 
myeloid BC have been reported to carry a mutation in the 
highly related human paralogue RUNX1, a gene critical for 
normal HSC activity that is commonly mutated in acute leu-
kemias (Grossmann et al., 2011). Functional redundancy has 
also previously been demonstrated between Runx1 and Runx2 
during mouse skeletal development (Smith et al., 2005), and 
our data suggest a similar complementation during transfor-
mation in our model. Another BC-specific CIS was Asxl1, a 
gene recurrently mutated or deleted in myeloid malignancies, 
including in 20% of CML myeloid BC (Boultwood et al., 
2010; Grossmann et al., 2011), and an interaction partner of 
the PRC2 gene repressive complex and negative regulator of 
HOXA cluster genes (Abdel-Wahab et al., 2012). Similarly, 
Myb, a critical HSPC transcription factor (Mucenski et al., 
1991) that has been described as important for BCR-ABL–
mediated transformation, CML leukemia stem cell (LSC) func-
tion and a proposed therapeutic target in CP and BC (Ratajczak 
et al., 1992; Lidonnici et al., 2008), was also a recurrent in-
sertion site in our BC cohort. So was Zfp423, a zinc finger 
transcription factor previously described as a recurrent inser-
tion site in a retroviral insertional mutagenesis model of BC 
(Miyazaki et al., 2009).
For many human tumors, our recent understanding of 
the mechanisms underlying de novo cancer formation and 
disease progression has been greatly informed by annotation of 
the mutational landscape in large numbers of patient samples, 
using NGS technology (Curtis et al., 2012; Cancer Genome 
Atlas Research Network, 2013). Unfortunately, in CML 
only a small number of directed (Grossmann et al., 2011) or 
single case exome NGS studies (Menezes et al., 2013; Huang 
et al., 2014) have been performed. CISs from our model 
overlap with these studies and also overlap significantly with 
mutations described for human BC cell lines in the CCLE, 
where 13 cell lines with available NGS data exhibited muta-
tions in 14/91 (15%) of our CISs (Table S5). These signifi-
cant overlaps, along with the strong molecular and cellular 
similarities to human CML progression, further validate the 
utility of our model to identify critical regulators of CML 
progression, and highlight that novel CISs identified in our 
screen may also be important for CML progression. Further 
investigation of these novel CISs and comparisons to human 
disease is warranted.
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Mouse transplantation experiments. Unfractionated BM cells (0.5–1 × 
106) from primary CML and BC cases were transplanted into sublethally 
irradiated (2 Gy) NOD-SCID mice, via tail vein injection. Similarly, ret-
rovirally transduced mouse progenitor cells were injected into sublethally 
irradiated (5 Gy) 8–12-wk-old FVB/N recipients via tail vein injection 
(106 cells/mouse).
Gene expression profiles and bioinformatic analysis. Gene expres-
sion profiling was performed using a Mouse WG-6 v2.0 expression bead-
chip kit according to the manufacturer’s protocol (Illumina). Illumina 
probe sequences were mapped against the mouse reference genome using 
BLAT. Data analysis was performed using the limma and lumi Bioconduc-
tor packages. Batch effects were corrected using COMBAT. Gene set en-
richment analysis tools were obtained from The Broad Institute. Default 
settings and all curated gene sets (c2.All.v4.0.symbols.gmt) were used for 
the analysis. Gene expression signatures were compared with CCLE 
(CCLE Broad Institute) human cell lines using the Enrichr tools (Chen 
et al., 2013a).
Identification of CISs. Preparation of genomic DNA, splinkerette PCR, 
and sequencing of barcoded samples have been previously described (Uren 
et al., 2009; March et al., 2011). In brief, genomic DNA from mouse leuke-
mias underwent restriction enzyme digestion and a splinkerette adaptor was 
added using ligation-mediated PCR. Leukemia samples were pooled and se-
quenced on the 454 GS-GLX platform, with each sample identifiable by a 
unique barcode, allowing deconvolution of the sequencing results for indi-
vidual cases. Pooled PCR reactions were sequenced on 454-GS-FLX se-
quencers (Roche). The bioinformatics pipeline used for quality control, 
sequence annotation, and mapping has been previously described (March 
et al., 2011). Statistically significant common insertion sites (CISs) were de-
termined using a Gaussian kernel convolution approach (de Ridder et al., 
2006; March et al., 2011) and chromosome significance cut-off levels of 
P < 0.05.
siRNA knockdown assays. Accell SMARTpool siRNA pools for 
VEGFC, MYB, as well as a nontargeting pool, were obtained from GE 
Dharmacon and delivered in human BC cell lines according to the manufac-
turer’s recommendations. In brief, human BC cell lines were resuspended in 
Accell Delivery Media at a concentration of 500,000 cells/ml. siRNA pools 
were resuspended in 1× siRNA buffer and added to the cell suspension at a 
final concentration of 1 µM. Cells were incubated for 48 h and subsequently 
plated in methylcellulose. mRNA levels were assessed 72 h after treatment 
using primer pairs found in Table S6.
Retroviral transduction assays. TransIT-LT1 transfection reagent (Mirus) 
was used to transfect the MSCV-ERG3-IRES-GFP vector (Diffner et al., 
2013) and the packaging plasmid psiEco into 293T cells according to the 
manufacturer’s protocol. PTEN (NM_00314) was cloned into an MSCV-
IRES-GFP vector and transduced into human cells using TransIT-LT1 and 
the amphotropic Phoenix 293T-derived cell line. Retroviral supernatants 
were collected at 48 and 72 h after transfection. BM cells from 8–12-wk-old 
BCR-ABL–expressing and WT FVB/N mice were selected for cell surface 
c-kit expression using CD117 MicroBeads (Miltenyi Biotec) according to 
the manufacturer’s protocol. Cells were spinoculated with retroviruses as 
previously described (Kvinlaug et al., 2011).
Cell culture and inhibitor assays. Meg-01, EM-2, Lama-84 and RPMI8866 
cells were grown in RPMI-1640 medium supplemented with FBS and 
penicillin/streptomycin (10–20 and 1% final concentration, respectively; 
Sigma-Aldrich). Mouse (20,000 cells/plate), human CML BC cell lines 
(1–5,000 cells/plate), and human CML BC patient primary cells (20–50,000 
cells/plate) were plated in duplicate using MethoCult GF M3434, Metho-
Cult H4531, and MethoCult H4435 enriched, respectively, in the pres-
ence of a small molecule inhibitor or DMSO. Colonies were scored at 
7–12 d.
genes involved in this progression, and identifies potential 
therapeutic targets. For many rare cancers, large human se-
quencing datasets are difficult or impossible to obtain and in-
deed, these datasets are not available for BC. Our model is 
therefore particularly welcome and will form an excellent re-
source to further our understanding of BC and to identify 
and model therapeutics for this aggressive disease.
MATERIALS AND METHODS
Mice. TRE-BCR-ABLTg/wt, SCLtTATg/wt (Koschmieder et al., 2005), and 
Mx1-CreTg/wt, GrOncTg/wt, and Rosa26flox-SB/wt (March et al., 2011; Vassiliou 
et al., 2011) were bred as illustrated in Fig. 1 A and Fig. S1 A. To suppress 
BCR-ABL expression, tetracycline hydrochloride (Sigma-Aldrich) was ad-
ministered in the drinking water (0.5 g/liter). Mx1-Cre–mediated inversion 
of the transposase was induced by intraperitoneal injection of 5 doses of 
pIpC (300 µg/dose; Sigma-Aldrich). Peripheral blood was collected from 
the saphenous vein into EDTA-coated tubes (Sarstedt). White blood counts 
(WBCs) were enumerated using a Vet abc counter (Scil Animal Care). All 
mice were housed in a pathogen-free animal facility and were allowed unre-
stricted access to food and water. All experiments were conducted in accor-
dance with UK (UK) Home Office regulations, under a UK Home Office 
project license.
PCR and qPCR. Total DNA and RNA was extracted using phenol/ 
chloroform (Invitrogen) and TRIzol (Ambion) methods, respectively. cDNA 
was synthesized using the SuperScript First-Strand RT-PCR kit (Invitro-
gen). All primers used for mouse genotyping and qPCR can be found in 
Table S6. Unless otherwise stated, PCR reaction conditions used 35 cycles 
and a 57°C annealing temperature. qPCR reactions were performed on a 
Stratagene MX 3000P qPCR system and data were analyzed using MXPro 
v4.10 software (Stratagene).
Histopathology. Tissues were fixed in a 10% formalin solution (CellPath 
Ltd.) and subsequently embedded in paraffin blocks. Bones were decalcified 
using 0.38 M EDTA (pH7) solution. Tissue sections (4 µm) were stained 
with Hematoxylin and Eosin (Thermo Fisher Scientific) according to the 
manufacturer’s protocol. Peripheral blood (PB) and BM cytopsin prepara-
tions were fixed in methanol and subsequently stained with Eosin Y and 
Methylene blue (Rapid Romanowsky Stain; TCS Biosciences Ltd.).
Flow cytometry assays. BM or spleen single-cell suspensions were pre-
pared as previously described (Chan et al., 2011) and stained with combinations 
of the following anti–mouse antibodies (BioLegend, unless otherwise stated): 
CD11b(Mac1) (FITC-conjugated; SouthernBiotech), CD4 (phycoerythrin 
[PE] conjugated), Ly-6G(Gr-1) (PE-Cy7 conjugated), CD45R(B220) (allo-
phycocyanin [APC]-conjugated; Invitrogen), CD117(c-kit) (PE-Cy7 con-
jugated), Ly-6A/E(Sca-1) (Pacific Blue [PB] conjugated), CD135(Flt3) (PE 
conjugated), CD34 (FITC conjugated; BD), CD127(IL-7Ra) (PE conju-
gated), CD16/32(FcRg) (PE conjugated), and Mouse Lineage antibody 
cocktail (APC conjugated; BD). LT-HSC, ST-HSC, MPP, CMP, GMP, 
and MEP were defined as previously described (Chan et al., 2011). All analy-
ses considered only 7-AAD (BD) populations. Annexin V (APC conju-
gated; BD) and 7-AAD were used in cell viability assays according to the 
manufacturer’s protocol. Flow cytometry was performed on a CyAn ADP 
FlowCytometer (Dako) or a BD LSRFortessa cell analyzer and all data were 
analyzed with FlowJo software (Tree Star).
Serial replating assays. Normal or leukemic mouse BM cells were plated 
at a concentration of 20,000 cells/plate (in duplicate) using MethoCult 
GF M3434 (STEMCELL Technologies) methylcellulose medium. Colonies 
were scored at 7–12 d and equal numbers of cells were replated using the 
same conditions.
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Chromatin immunoprecipitation (ChIP) and ChIP-PCR assays. 
ChIP was performed on human CML BC cells harvested 24–48 h after treat-
ment as previously described (Dawson et al., 2011). In brief, 107 cells were 
fixed in 1% formaldehyde for 15 min at room temperature. The cross-linking 
reaction was stopped by addition of glycine (0.125 M final concentration) 
and additional incubation of 10 min. Cells were washed in PBS and cell pel-
lets were lysed in lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-HCl, 
pH 8.0, and 1 mM sodium orthovanadate and protease inhibitors). Chroma-
tin was sonicated in a Bioruptor (Diagenode) sonicator and precleared for 
1 h before immunoprecipitation in equal volumes of protein A and G beads 
(Dynabeads; Life Technologies). Immunoprecipitation was performed at 
4°C overnight in modified RIPA buffer (1% Triton X-100, 0.1% deoxycho-
late, 0.1% SDS, 90 mM NaCl, 10 mM Tris-HCl pH 8.0, 1 mM sodium or-
thovanadate, and EDTA-free protease inhibitors) in the presence 2.5 µg of 
IgG (I5006; Sigma-Aldrich) or c-Myc (sc-764; Santa Cruz Biotechnology) 
antibodies and A/G beads. DNA was subsequently RNase treated, reverse 
cross-linked, and purified using QIAquick PCR purification kit (QIAGEN). 
ChIP-PCR was performed with SYBR Green PCR mastermix using the 
ABI Prism 7000 system (Applied Biosystems). The primers used can be 
found in Table S6.
Patient material. Patient BM or peripheral blood cells (>80% blasts) were 
obtained after donor/patient consent and under full ethical approval.
Statistical analysis. Unless otherwise stated, all statistical analyses used Stu-
dent’s t test on raw data. P-values ≤ 0.05 were considered statistically signifi-
cant. Survival curves were constructed using the Kaplan-Meier method and 
statistical significance was determined using log-rank analysis.
Online supplemental material. Table S1 lists the differentially expressed 
genes between BC and CML BM samples (adjusted P < 0.05). Table S2 
contains the BC CIS list (P < 0.05). Table S3 shows the SB CIS list (P < 
0.05). Table S4 contains the CML BC patient details that were used in Fig. 9. 
Table S5 shows the overlapping mutations between our BC CIS and several 
human CML BC cell lines (as reported in CCLE). All primer sequences that 
were used in this study can be found in Table S5. All tables are available as 
Excel files. Fig. S1 shows the breeding strategy to generate the parental 
mouse lines and plots of the HSC composition in CML and BC mice as assessed 
by flow cytometry. Online supplemental material is available at http://www 
.jem.org/cgi/content/full/jem.20141661/DC1.
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